Bio-Techne Future Growth
Future criteria checks 1/6
Bio-Techne is forecast to grow earnings and revenue by 9.9% and 7.7% per annum respectively. EPS is expected to grow by 9.4% per annum. Return on equity is forecast to be 14.5% in 3 years.
Key information
9.9%
Earnings growth rate
9.4%
EPS growth rate
Life Sciences earnings growth | 16.3% |
Revenue growth rate | 7.7% |
Future return on equity | 14.5% |
Analyst coverage | Good |
Last updated | 11 Feb 2024 |
Recent future growth updates
Recent updates
We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29Bio-Techne releases Quantist Luminex data analysis software
Aug 18Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Aug 16Bio-Teche announces transition plan for CEO Kummeth
Aug 04Bio-Techne: Resiliency Comes At A Large Premium
Jul 29Bio-Techne launches HPV detection test RNAscope in Europe for use in throat cancer
Jul 06Should You Think About Buying Bio-Techne Corporation (NASDAQ:TECH) Now?
Jun 22Is Bio-Techne (NASDAQ:TECH) Using Too Much Debt?
Jun 09Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
May 26Estimating The Fair Value Of Bio-Techne Corporation (NASDAQ:TECH)
May 13Bio-Techne - Exceptional Leverage To Biopharma Growth, And Priced Accordingly
Mar 23Is Bio-Techne (NASDAQ:TECH) A Risky Investment?
Mar 08Here's Why I Think Bio-Techne (NASDAQ:TECH) Is An Interesting Stock
Feb 21Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2026 | 1,383 | 265 | 350 | 405 | 10 |
6/30/2025 | 1,248 | 226 | 332 | 386 | 13 |
6/30/2024 | 1,148 | 177 | 263 | 315 | 14 |
12/31/2023 | 1,145 | 224 | 225 | 276 | N/A |
9/30/2023 | 1,144 | 247 | 215 | 258 | N/A |
6/30/2023 | 1,137 | 285 | 216 | 254 | N/A |
3/31/2023 | 1,124 | 271 | 233 | 274 | N/A |
12/31/2022 | 1,120 | 262 | 252 | 296 | N/A |
9/30/2022 | 1,118 | 292 | 285 | 333 | N/A |
6/30/2022 | 1,106 | 272 | 280 | 325 | N/A |
3/31/2022 | 1,076 | 225 | 302 | 345 | N/A |
12/31/2021 | 1,030 | 210 | 308 | 346 | N/A |
9/30/2021 | 985 | 177 | 295 | 335 | N/A |
6/30/2021 | 931 | 140 | 308 | 352 | N/A |
3/31/2021 | 848 | 184 | 225 | 275 | N/A |
12/31/2020 | 799 | 175 | 201 | 250 | N/A |
9/30/2020 | 760 | 248 | 179 | 231 | N/A |
6/30/2020 | 739 | 229 | 153 | 205 | N/A |
3/31/2020 | 755 | 187 | 170 | 216 | N/A |
12/31/2019 | 745 | 195 | 165 | 207 | N/A |
9/30/2019 | 734 | 93 | 151 | 183 | N/A |
6/30/2019 | 714 | 96 | 156 | 182 | N/A |
3/31/2019 | 703 | 121 | 171 | 191 | N/A |
12/31/2018 | 682 | 96 | 154 | 173 | N/A |
9/30/2018 | 661 | 128 | 145 | 165 | N/A |
6/30/2018 | 643 | 126 | 149 | 170 | N/A |
3/31/2018 | 619 | 112 | 135 | 156 | N/A |
12/31/2017 | 599 | 114 | 138 | 160 | N/A |
9/30/2017 | 577 | 73 | N/A | 162 | N/A |
6/30/2017 | 563 | 76 | N/A | 144 | N/A |
3/31/2017 | 541 | 74 | N/A | 129 | N/A |
12/31/2016 | 528 | 82 | N/A | 141 | N/A |
9/30/2016 | 517 | 101 | N/A | 138 | N/A |
6/30/2016 | 499 | 104 | N/A | 144 | N/A |
3/31/2016 | 482 | 105 | N/A | 145 | N/A |
12/31/2015 | 465 | 99 | N/A | 138 | N/A |
9/30/2015 | 456 | 107 | N/A | 135 | N/A |
6/30/2015 | 452 | 108 | N/A | 139 | N/A |
3/31/2015 | 427 | 108 | N/A | 140 | N/A |
12/31/2014 | 408 | 116 | N/A | 144 | N/A |
9/30/2014 | 380 | 107 | N/A | 140 | N/A |
6/30/2014 | 358 | 111 | N/A | 137 | N/A |
3/31/2014 | 345 | 113 | N/A | 129 | N/A |
12/31/2013 | 330 | 114 | N/A | 127 | N/A |
9/30/2013 | 321 | 114 | N/A | 127 | N/A |
6/30/2013 | 311 | 113 | N/A | 124 | N/A |
3/31/2013 | 310 | 111 | N/A | 131 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TECH's forecast earnings growth (9.9% per year) is above the savings rate (2.3%).
Earnings vs Market: TECH's earnings (9.9% per year) are forecast to grow slower than the US market (13.5% per year).
High Growth Earnings: TECH's earnings are forecast to grow, but not significantly.
Revenue vs Market: TECH's revenue (7.7% per year) is forecast to grow slower than the US market (8.2% per year).
High Growth Revenue: TECH's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TECH's Return on Equity is forecast to be low in 3 years time (14.5%).